We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Alkermes plc is one of them.
Alkermes plc (NASDAQ:ALKS) tops our list for being one of the best psychedelic stocks. It is an Ireland-based biopharmaceutical company with U.S. operations, and specializes in treatments for complex psychiatric and neurological conditions, including alcohol and opioid dependence, schizophrenia, and bipolar I disorder. The company leverages its neuroscience expertise to develop innovative therapies, with an active pipeline targeting disorders such as narcolepsy and idiopathic hypersomnia.
A major focus is alixorexton (formerly ALKS 2680), a novel oral orexin 2 receptor agonist currently in Phase 2 trials for narcolepsy types 1 and 2, as well as idiopathic hypersomnia. Enrollment in the Vibrance-1 Phase 2 study for narcolepsy type 1 has been completed, with topline data expected in early Q3 2025. Early Phase 1/1b results indicate the drug is well-tolerated, improves wakefulness, and shows no cardiac safety concerns. Detailed findings will be presented at the World Sleep Congress 2025, highlighting patient-reported outcomes and efficacy. This development underscores Alkermes plc (NASDAQ:ALKS)’ commitment to addressing unmet needs in sleep disorders.
Image Point Fr/Shutterstock.com
Alongside pipeline progress, Alkermes plc (NASDAQ:ALKS) continues strong commercial performance with products like VIVITROL, ARISTADA, and LYBALVI, the latter showing notable year-over-year revenue growth. The company reinvests profits into research and development rather than dividends, maintaining a robust cash position to support innovation. Recent survey findings on alcohol use disorder further illustrate the corporation’s patient-centric approach, emphasizing its strategic focus on combining commercial success with cutting-edge neuroscience therapies
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure. None.
